康臣药业(01681.HK)2020年纯利大增524.9%至4.99亿元 末期息0.2港元
格隆汇3月23日丨康臣药业(01681.HK)公布,截至2020年12月31日止年度,公司实现收入17.53亿元人民币(单位下同),同比增长1.4%;公司权益股东应占溢利4.99亿元,同比增长524.9%,倘扣除去年非现金项目的商誉及无形资产减值3.2亿元影响,同比增长23.5%;每股基本盈利0.61元,宣派末期股息每股0.20港元。
按产品系列分类,肾科系列产品销售较去年录得增长约9.7%,其中尿毒清颗粒仍然是集团的皇牌产品,维持在肾病口服现代中成药的领先地位;医用成像对比剂销售较去年减少约3.0%,仍稳占国内磁共振成像对比剂市场的前列;骨伤系列产品销售增长约19.5%;皮肤系列产品销售减少约47.0%;肝胆系列产品销售增长约13.2%;妇儿系列产品销售增长约6.2%。整体销售收入的增长主要是由于集团持续致力开拓产品市场以及发展全国各地的销售网络所致。
康臣业现在拥有“1+6”的产品格局,四条过亿元产品线分别是肾科线(尿毒清颗粒、益肾化湿颗粒)、影像线(钆喷酸葡胺注射液、碘帕醇注射液)、骨伤科(正骨水、云香祛风止痛酊)及妇儿线(右旋糖酐铁口服溶液),预计消化线(缓痛止泻软胶囊等)1-2年内销售额达到亿元以上,各线均有主打的、重磅的产品。
2020年,公司利用自有资金不断回购股票,全年共计回购了4590.7万股股票,占回购前总股本约5.30%,对自身股票的持续、大比例回购,既是对公司价值的认可和未来发展的坚定信心,也是对广大投资者利益的保护,同时向资本市场传递积极正面的企业形象,是一项一举多赢的战略举措。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.